AbbVie Raises Profit Forecast After Strong Q3 Sales
Strong sales of immunology drugs prove the company's transition beyond its legacy Humira portfolio is accelerating.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies that rely heavily on a few top-selling drugs for growth?
AbbVie raised its annual profit forecast after reporting strong third-quarter results driven by high sales of its flagship immunology drugs. The company reported $17.40 billion in quarterly revenue, signaling a successful pivot following the loss of Humira's US patent exclusivity in 2023.
Why it matters
The performance confirms that AbbVie's transition to newer immunology and neuroscience treatments is effectively offsetting revenue declines from its legacy products. This growth trajectory is being reinforced by aggressive R&D investments and high-value acquisitions designed to sustain long-term earnings.
The company reported $5.78 billion in sales for Skyrizi and $2.71 billion for Rinvoq, significantly outperforming legacy portfolios. Neuroscience revenue also climbed 19% to $3.39 billion.
The players
AbbVie
A global biopharmaceutical company focusing on immunology, neuroscience, and oncology through its internal drug pipeline and strategic acquisitions.
Apogee Therapeutics
A biotechnology firm developing advanced protein engineering technologies for immunological conditions.
The details
AbbVie manages its revenue transition by leveraging a high-growth immunology stack comprised of Skyrizi and Rinvoq. Skyrizi is a monoclonal antibody — a laboratory-made molecule designed to target specific proteins in the immune system — that replaced Humira as the company's primary growth engine. To extend this runway, the company acquired Apogee Therapeutics for $10.9 billion in June 2026, shifting capital toward advanced biological pipelines.
Timeline
2023: Humira lost US patent exclusivity.
June 2026: AbbVie acquired Apogee Therapeutics.
October 29, 2026: AbbVie shares reached a record high of $290.79.
October 30, 2026: AbbVie raised its annual profit forecast.
2032: Apogee acquisition is expected to begin contributing to earnings.
The Tech Race
AbbVie is currently navigating a high-stakes transition from the legacy success of Humira to a next-generation immunology portfolio. The company is betting its growth on maintaining this expansion while integrating the specialized pipeline gained from the Apogee Therapeutics acquisition.
The company's performance reinforces the availability of advanced biologics for patients with chronic immunological and neurological conditions. These drugs remain the primary standard of care as the company continues to scale its manufacturing and delivery infrastructure.
The takeaway
AbbVie has successfully pivoted its business model to offset the loss of its blockbuster Humira patent. Observers should track the integration of the Apogee Therapeutics pipeline as a key indicator for the company's long-term earnings potential through 2032.
What happens next
Investors and stakeholders should monitor the impact of the Apogee Therapeutics acquisition on annual profit margins through the 2027 fiscal year.
Further reading
For more on the industry shift toward newer immunological therapies, visit the Biotech section.
Live Poll
Do you trust pharmaceutical companies that rely heavily on a few top-selling drugs for growth?
